Get the Stockscreener App
6.83
1.01%
-0.07
After Hours:
6.83
Teladoc Health Inc stock is traded at $6.83, with a volume of 3.83M.
It is down -1.01% in the last 24 hours and down -23.00% over the past month.
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
See More
Previous Close:
$6.90
Open:
$6.85
24h Volume:
3.83M
Relative Volume:
0.51
Market Cap:
$1.27B
Revenue:
$2.59B
Net Income/Loss:
$-981.73M
P/E Ratio:
-1.1837
EPS:
-5.77
Net Cash Flow:
$206.95M
1W Performance:
-5.66%
1M Performance:
-23.00%
6M Performance:
-28.18%
1Y Performance:
-48.02%
1-Day Range:
$6.7625
$6.96
1-Week Range:
$6.7625
$7.42
52-Week Range:
$6.61
$15.21
Teladoc Health Inc Stock (TDOC) Company Profile
Name
Teladoc Health Inc
Sector
Industry
Phone
(203) 635-2002
Address
2 MANHATTANVILLE ROAD, PURCHASE, NY
Compare TDOC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TDOC
Teladoc Health Inc
|
6.83 | 1.27B | 2.59B | -981.73M | 206.95M | -5.77 |
|
VEEV
Veeva Systems Inc
|
215.95 | 36.39B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
53.21 | 9.87B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
40.45 | 7.46B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
84.52 | 7.21B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.45 | 6.30B | 906.14M | -52.62M | 89.62M | -0.3621 |
Teladoc Health Inc Stock (TDOC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Goldman | Buy |
| Sep-17-24 | Reiterated | Jefferies | Hold |
| Feb-29-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Jan-17-24 | Downgrade | DA Davidson | Buy → Neutral |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Apr-12-23 | Initiated | Stephens | Equal-Weight |
| Feb-23-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Oct-24-22 | Upgrade | Guggenheim | Sell → Neutral |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-07-22 | Initiated | Truist | Hold |
| Aug-17-22 | Downgrade | Guggenheim | Neutral → Sell |
| Aug-12-22 | Initiated | DA Davidson | Buy |
| Aug-02-22 | Downgrade | Berenberg | Buy → Hold |
| Aug-02-22 | Downgrade | Cowen | Outperform → Market Perform |
| Jul-28-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-28-22 | Downgrade | Needham | Buy → Hold |
| Jul-06-22 | Reiterated | BofA Securities | Neutral |
| May-05-22 | Downgrade | Argus | Buy → Hold |
| Apr-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Apr-28-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-28-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-28-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-28-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-07-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-03-22 | Upgrade | Argus | Hold → Buy |
| Feb-23-22 | Reiterated | BofA Securities | Neutral |
| Feb-23-22 | Reiterated | Craig Hallum | Hold |
| Feb-23-22 | Reiterated | Evercore ISI | In-line |
| Feb-23-22 | Reiterated | Goldman | Buy |
| Feb-23-22 | Reiterated | JP Morgan | Overweight |
| Feb-23-22 | Reiterated | KeyBanc Capital Markets | Overweight |
| Feb-23-22 | Reiterated | Needham | Buy |
| Feb-23-22 | Reiterated | Oppenheimer | Outperform |
| Feb-23-22 | Reiterated | Stifel | Hold |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-08-22 | Reiterated | Piper Sandler | Overweight |
| Dec-02-21 | Resumed | Jefferies | Hold |
| Nov-22-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-28-21 | Reiterated | Barclays | Equal Weight |
| Oct-28-21 | Reiterated | BofA Securities | Neutral |
| Oct-28-21 | Reiterated | Canaccord Genuity | Buy |
| Oct-28-21 | Reiterated | Citigroup | Buy |
| Oct-28-21 | Reiterated | Craig Hallum | Hold |
| Oct-28-21 | Reiterated | Needham | Buy |
| Oct-28-21 | Reiterated | Oppenheimer | Outperform |
| Oct-28-21 | Reiterated | Piper Sandler | Overweight |
| Oct-28-21 | Reiterated | UBS | Neutral |
| Oct-19-21 | Initiated | Wells Fargo | Overweight |
| Aug-02-21 | Downgrade | Argus | Buy → Hold |
| Jul-28-21 | Downgrade | Deutsche Bank | Buy → Hold |
| May-28-21 | Initiated | Robert W. Baird | Neutral |
| Apr-15-21 | Initiated | Needham | Buy |
| Jan-07-21 | Initiated | BTIG Research | Buy |
| Dec-22-20 | Initiated | Evercore ISI | In-line |
| Dec-07-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| Dec-04-20 | Initiated | Goldman | Neutral |
| Nov-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-22-20 | Initiated | DA Davidson | Buy |
| Sep-02-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-17-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-14-20 | Initiated | Citigroup | Buy |
| Jul-13-20 | Initiated | Argus | Buy |
| Jul-07-20 | Initiated | Stephens | Overweight |
| Apr-30-20 | Reiterated | KeyBanc Capital Markets | Overweight |
| Apr-13-20 | Initiated | SVB Leerink | Outperform |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-25-20 | Downgrade | Craig Hallum | Buy → Hold |
| Mar-16-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-12-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-28-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Feb-12-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-10-20 | Initiated | UBS | Neutral |
| Jan-09-20 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Teladoc Health Inc Stock (TDOC) Latest News
Telestroke Services Market Set to Witness Significant Growth by 2025-2032 | ScienceSoft, SEVARO, Teladoc Health - openPR.com
Teladoc Health to Announce First Quarter 2025 Financial Results | TDOC Stock News - GuruFocus
Teladoc Health Inc. to Release First Quarter 2025 Results on April 30, 2025 - Nasdaq
Teladoc Health to Announce First Quarter 2025 Financial Results - GlobeNewswire
Virtual Care Leader Teladoc Health Sets Q1 2025 Earnings Release DateKey Details Inside - Stock Titan
Teladoc: Back In The Doldrums After Another Tough Year (Rating Downgrade) (NYSE:TDOC) - Seeking Alpha
Emerging Trends in Video Consultation Medical Service Market - openPR.com
Hims & Hers Stock Gains 5.8% in 3 Months: Here's How to Play it - TradingView
Future Scope of Virtual Healthcare Home Market to Observe - openPR.com
Virtual Care Services Market Projected To Witness Massive - openPR.com
2 Beaten-Down Stocks to Avoid in the Tariff-Fueled Correction - MSN
Teladoc (TDOC) Experiences Increased Option Activity Ahead of Ea - GuruFocus
BofA Revises Teladoc (TDOC) Price Target Amid Weaker Growth and Strategic Initiatives | TDOC Stock News - GuruFocus
Forecasting The Future: 8 Analyst Projections For Teladoc Health - Benzinga
Lobbying Update: $10,000 of TELADOC HEALTH INC. lobbying was just disclosed - Nasdaq
Teladoc Health Launches New Cardiometabolic Health Program - MedCity News
Unparalleled Research on Behavioral Health Telehealth Market - openPR.com
Digital Health Market Projected To Witness Substantial Growth, - openPR.com
Teladoc (TDOC) Stock Moves -0.97%: What You Should Know - Yahoo Finance
Teladoc Health CFO Murthy Mala sells $51,011 in stock By Investing.com - Investing.com South Africa
Teladoc Health CFO Murthy Mala sells $51,011 in stock - Investing.com
Trend Tracker for (TDOC) - news.stocktradersdaily.com
Teladoc unveils virtual care tool for cardiometabolic health - TechTarget
Digital health startup Transcarent takes Accolade private in $621 million deal - CNBC
Teladoc Health Introduces Next Generation Cardiometabolic Health Program - GlobeNewswire
Revolutionary: New Teladoc Health Program Achieves 58% Diabetes Remission Levels - Stock Titan
Teladoc Stock Plummets to 52-Week Low of $6.76 Amid Market Challenges - Investing.com India
Teladoc Health, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 16, 2024 to Discuss Your Rights – TDOC - ACCESS Newswire
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks? - AOL.com
Major Player in the Teletherapy Platform Integration Market - openPR.com
Teladoc (TDOC) Gains But Lags Market: What You Should Know - Yahoo Finance
Teladoc Health, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 16, 2024 to Discuss Your RightsTDOC - ACCESS Newswire
Teladoc Health (NYSE:TDOC) Expands Connected Care Partnerships Amid US Tariff Concerns - Yahoo Finance
Hims & Hers to sell Lilly's Zepbound on its telehealth platform - Yahoo Finance
Virtual Care Market Forecasted for Major Expansion by 2031 | - openPR.com
Chronic Disease Management Market Opportunity Potential: - openPR.com
(TDOC) On The My Stocks Page - Stock Traders Daily
Why Is Teladoc (TDOC) Down 9.9% Since Last Earnings Report? - Yahoo Finance
Future Business Opportunities in Enterprise Telemedicine - openPR
Telepsychiatry Market 2025: Sustainable Growth, Key Trends, - openPR
Telestroke Services Market to Witness Remarkable Growth with ScienceSoft, SEVARO, Teladoc Health, Inc - openPR
Global Telehealth Services Market Is Booming So Rapidly - openPR
Teladoc (TDOC) Flat As Market Sinks: What You Should Know - Yahoo Finance
Best Statistical Video-Based Mental Health Platforms Market - openPR
Teladoc's Meltdown May Not Be Over YetMinimal Growth Opportunities (NYSE:TDOC) - Seeking Alpha
Teladoc (TDOC): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
U.S. Telehealth Counseling Market Projected To Witness - openPR
North America Telemedicine Market Major Manufacturers, Trends, Demand, Share Analysis to 2028 - openPR
Teladoc Beats Investor Suit For Good On 2nd Circ. Remand - Law360
Teladoc Defeats Securities Class Suit Over Livongo Merger Again - Bloomberg Law
Digital Therapeutics Market Size, Growth Trends & Forecast - openPR
Teladoc Health Inc Stock (TDOC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):